Production (Stage)
Mydecine Innovations Group Inc.
MYCO
CNSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -58.69% | -70.47% | -68.73% | -68.77% | -58.31% |
| Depreciation & Amortization | -- | -- | -100.00% | -97.22% | -94.01% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -64.21% | -73.23% | -46.88% | -57.21% | -59.50% |
| Operating Income | 64.21% | 73.23% | 46.88% | 57.21% | 59.50% |
| Income Before Tax | 78.63% | 84.75% | 33.93% | 43.97% | 45.09% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 78.63% | 84.75% | 33.93% | 43.97% | 45.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 78.63% | 84.75% | -3.31% | 18.53% | 20.55% |
| EBIT | 64.21% | 73.23% | 46.88% | 57.21% | 59.50% |
| EBITDA | 69.88% | 73.31% | 46.87% | 57.12% | 59.35% |
| EPS Basic | 86.55% | 93.55% | 56.58% | 71.77% | 73.83% |
| Normalized Basic EPS | 80.23% | 85.90% | 71.10% | 77.18% | 77.77% |
| EPS Diluted | 86.55% | 93.55% | 56.58% | 71.77% | 73.83% |
| Normalized Diluted EPS | 80.23% | 85.90% | 71.10% | 77.18% | 77.77% |
| Average Basic Shares Outstanding | 56.73% | 95.51% | 165.88% | 193.32% | 228.42% |
| Average Diluted Shares Outstanding | 56.73% | 95.51% | 165.88% | 193.32% | 228.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |